LOXO-195 is an orally available, highly potent, and selective TRK kinase inhibitor designed to overcome drug resistance mediated by acquired mutations. Although responses to TRK inhibition can be dramatic and durable; however, eventually emergence of acquired resistance is found to be inevitable.
